Interleukin-1β (IL-1β)

Overview

Interleukin-1 beta (IL-1β), encoded by the IL1B gene (Wikidata: Q411529), is a pro-inflammatory cytokine of the interleukin-1 family and one of the principal drivers of fever and systemic inflammation. It is produced chiefly by activated macrophages, monocytes, and dendritic cells, and its release requires two separate signals. The first, typically a Toll-like receptor engaging nuclear factor kappa B (NF-κB), transcribes an inactive 31 kDa precursor; the second assembles an inflammasome such as the NLRP3 inflammasome, which activates caspase-1 (CASP1) to cleave that precursor into the 17 kDa mature form. Because IL-1β carries no signal peptide it cannot leave by the secretory pathway, and exits instead through Gasdermin D (GSDMD) pores in the plasma membrane. This two-key arrangement is what keeps a cytokine this destructive from being released on transcription alone.

Mature IL-1β signals through IL-1R1 in complex with the accessory protein IL-1RAcP, recruiting MyD88 and the IRAK kinases to activate NF-κB and MAPK cascades. The transcriptional response includes further inflammatory mediators such as interleukin-6 and tumor necrosis factor alpha, and the enzymes that generate prostaglandins, notably cyclooxygenase-2 — IL-1β induces the machinery rather than the lipid mediators themselves. The system is restrained at several points: the receptor antagonist IL-1Ra occupies IL-1R1 without signaling, and the decoy receptor IL-1R2 binds the cytokine without transducing.

Sustained IL-1β production underlies chronic inflammatory and fibrotic disease, including rheumatoid arthritis, sepsis-associated organ injury, neurodegeneration, metabolic disease, and diabetic complications, and it works within a network alongside TNF, interleukin-6, and Interleukin 18 (IL-18). Blockade is clinically established rather than prospective: recombinant IL-1Ra, an IL-1β-neutralizing antibody, and a soluble receptor trap are used in the hereditary autoinflammatory syndromes, where the response is near-complete, and in gout and adult-onset Still disease. Trial evidence that IL-1β blockade lowers recurrent cardiovascular events independently of lipid lowering established inflammation itself as a treatable cardiovascular target. Measurement of the cytokine — in serum, urine, or tissue homogenates — may serve as a pharmacodynamic or diagnostic biomarker in selected contexts, though its short half-life and low circulating concentrations limit routine use.

Recent Publications Summary

Recent publications have continued to position Interleukin-1β (IL-1β) as a central inflammatory target across neurodegenerative, renal, oral, and cardiovascular contexts. In an Alzheimer's disease-focused network pharmacology and molecular docking study, IL1B emerged among the 14 key overlapping targets linking gut microbiota-derived metabolites to immune-inflammatory pathways, and it was also identified as a central hub gene in the protein-protein interaction network alongside IL6, NFKB1, and CXCL8 42406869Jul. The same analysis associated these targets with immune-inflammatory responses, oxidative stress, apoptosis regulation, and signaling pathways including NOD-like receptor, TNF, NF-κB, and MAPK 42406869Jul. Related neuroinflammation studies also evaluated IL-1β as a biomarker or mechanistic readout in cognitive impairment models, including work on trans-anethole in AlCl3-induced memory impairment and on empagliflozin/dapagliflozin in diabetic cognitive dysfunction, where IL-1β was measured among inflammatory endpoints in brain tissue 42154340May41819428Mar.

Several recent studies examined IL-1β in kidney and inflammatory disease settings. In IgA nephropathy, IL1B was one of six hub genes with high diagnostic accuracy in a pyroptosis-related bioinformatics analysis, and the gene set was linked to immune response, cell migration, and inflammation-related signaling pathways 42135973May. In sickle cell disease, urinary IL-1β was investigated as a potential early biomarker for renal dysfunction and sickle nephropathy, with the study specifically aiming to relate urinary IL-1β to established markers of renal damage 42095901May. In periodontitis, IL1B+ macrophages were highlighted as a pro-inflammatory subset associated with tissue destruction, and a repurposing study found that azilsartan medoxomil attenuated periodontitis by targeting SERPINB9 to promote apoptosis of these IL1B+ macrophages 41864017Mar. A separate systematic review and meta-analysis also assessed systemic cytokine alterations in periodontitis, reflecting broader interest in circulating inflammatory mediators including IL-1β 41910651Mar.

IL-1β was also implicated in oxidative stress-linked tissue injury and inflammatory remodeling. In a mouse model of polystyrene nanoplastic exposure, hippocampal damage and cognitive deficits were associated with increased TNF-α and IL-1β, alongside microglial extracellular trap formation and neuronal ferroptosis 42070744May. In vitiligo research, oxidative stress in dermal fibroblasts activated the cGAS-STING pathway and the NLRP3 inflammasome, driving expression of IL-1β together with IL-6 and other inflammatory markers 41722540Feb. In calcific aortic valve disease, IL-1β was described as regulating miR-132 in the context of dysregulated apoptosis and inflammation, and engineered exosomes were developed to counter these pathways 41985595Apr. In a study of wine-processed Radix Paeoniae Rubra, molecular docking suggested strong binding of enriched polyphenols to IL-1β, IL-6, and TNF-α, supporting the herb’s anti-inflammatory profile 42000152Apr.

Across these publications, IL-1β was repeatedly used as a biomarker, mechanistic mediator, or therapeutic target rather than as a standalone intervention. The studies collectively linked IL-1β to immune-inflammatory signaling, pyroptosis, oxidative stress, macrophage activation, and neurodegeneration, with recurring connections to pathways such as NLRP3 inflammasome, NF-κB, MAPK, and cGAS-STING 42406869Jul42135973May42070744May41722540Feb.

What Changes, What Holds

1. IL1B is now being used as a hub marker for neuroinflammatory network models rather than only a generic inflammatory mediator
NEW DIRECTION Recent work places IL1B in disease-network and docking frameworks for cognitive decline, where it functions as a central node alongside other inflammatory genes and pathways. That does not displace the established cytokine biology, but it does extend IL-1β into a more specific systems-biology role in Alzheimer’s-related hypothesis generation and biomarker selection 42406869Jul. The cognitive-impairment studies also keep IL-1β in the familiar biomarker space, reinforcing its use as a readout of brain inflammation 42154340May41819428Mar.

2. IL1B is emerging as a candidate renal and periodontal biomarker, but the evidence is still associative
NEW DIRECTION These studies broaden IL-1β beyond the Overview’s general biomarker framing by tying it to kidney-risk stratification in IgA nephropathy and sickle nephropathy, and to macrophage-driven periodontal destruction. That adds organ-specific utility, not a contradiction of the baseline. The renal and oral findings are still largely bioinformatic or correlative, so they support hypothesis generation more than clinical deployment 42135973May42095901May. The macrophage subset result also suggests a more cell-state-specific inflammatory role 41864017Mar.

3. IL1B continues to mark oxidative-stress injury across diverse tissues, strengthening its role as a downstream inflammatory readout
REINFORCES The new studies do not revise IL-1β biology; they show it rising alongside oxidative stress, ferroptosis, inflammasome activation, and tissue remodeling in several models. That fits the Overview’s account of IL-1β as a mediator within broader inflammatory networks and as a widely used biomarker. The added value is mainly contextual: IL-1β is being repeatedly used to track injury mechanisms in brain, skin, and valve disease rather than being proposed as a new class of target 42070744May41722540Feb.

4. These papers mostly extend IL1B as a mechanistic marker and therapeutic target, not a new intervention class
REINFORCES Across the set, IL-1β is repeatedly treated as a readout of inflammasome- and NF-κB-linked inflammation, which is exactly the kind of role the Overview already assigns to it. The recurring appearance of IL-1β in biomarker panels, pathway analyses, and anti-inflammatory targeting strategies sharpens that picture but does not overturn it. What remains unsettled is whether any of these disease-specific associations will translate into actionable clinical specificity beyond the broad inflammatory use already established 42406869Jul42135973May.